PRKN and Hepatic steatosis: Another report suggests that activation of PINK1 is more closely related to DNM1L-mediated mitofission and quality control independent of PRKN that leads to metabolic diseases such as insulin resistance, type 2 diabetes, and fatty liver (Axelrod et al., 2021)